VVYA Stock Overview
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vivoryon Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.91 |
| 52 Week High | €7.66 |
| 52 Week Low | €7.59 |
| Beta | 1.28 |
| 1 Month Change | 81.50% |
| 3 Month Change | -89.73% |
| 1 Year Change | -93.85% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| VVYA | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 4.8% | 1.3% |
| 1Y | -93.9% | -28.8% | 3.5% |
Return vs Industry: VVYA underperformed the UK Biotechs industry which returned -25.7% over the past year.
Return vs Market: VVYA underperformed the UK Market which returned 1.9% over the past year.
Price Volatility
| VVYA volatility | |
|---|---|
| VVYA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: VVYA's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine VVYA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 15 | Frank Weber | www.vivoryon.com |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease.
Vivoryon Therapeutics N.V. Fundamentals Summary
| VVYA fundamental statistics | |
|---|---|
| Market cap | €16.89m |
| Earnings (TTM) | -€28.34m |
| Revenue (TTM) | n/a |
-4.7x
P/S Ratio-0.6x
P/E RatioIs VVYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VVYA income statement (TTM) | |
|---|---|
| Revenue | -€3.62m |
| Cost of Revenue | -€525.00k |
| Gross Profit | -€3.09m |
| Other Expenses | €25.25m |
| Earnings | -€28.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.09 |
| Gross Margin | 85.50% |
| Net Profit Margin | 782.93% |
| Debt/Equity Ratio | 0% |
How did VVYA perform over the long term?
See historical performance and comparison